GF Fund Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$93.3K Buy
3,529
+903
+34% +$23.6K ﹤0.01% 340
2026
Q2
$68.9K Sell
2,626
-125
-5% -$2.91K ﹤0.01% 363
2026
Q1
$64.8K Buy
2,751
+345
+14% +$8.8K ﹤0.01% 374
2025
Q4
$69.9K Sell
2,406
-174
-7% -$4.45K ﹤0.01% 375
2025
Q3
$48.6K Sell
2,580
-416
-14% -$6.56K ﹤0.01% 398
2025
Q2
$42K Hold
2,996
– – ﹤0.01% 434
2025
Q1
$46.9K Buy
2,996
+538
+22% +$7.58K ﹤0.01% 428
2024
Q4
$34.2K Buy
+2,458
New +$26.9K ﹤0.01% 425

Other funds holding ARQT

GF Fund Management's ARQT Position: Q3 2026 in Review

GF Fund Management increased its Arcutis Biotherapeutics (ARQT) stake by 34% in Q3 2026, buying an estimated $23.6K and bringing the position to 3,529 shares worth $93.3K. The position accounts for ﹤0.01% of the portfolio, ranked #340.

GF Fund Management first reported a position in ARQT in Q4 2024 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • GF Fund Management held 3,529 shares of Arcutis Biotherapeutics worth $93.3K as of Q3 2026.
  • GF Fund Management bought 903 Arcutis Biotherapeutics shares in Q3 2026, an estimated $23.6K.
  • Arcutis Biotherapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #340 holding.
  • GF Fund Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.